Alnylam Pharmaceuticals Inc develops RNA interference (RNAi) therapeutics for genetically defined diseases, primarily serving markets in the U.S. and Europe. The company commercializes RNAi-based medicines for rare and prevalent diseases with unmet medical needs.
Some research tools need a free Smallfolk account or a Smallfolk Pro plan.